KPV has demonstrated bioavailability via both oral and subcutaneous administration
However, neither formulation achieved the predefined clinical thresholds (2.5 kg weight loss, 1.0 kg/m 2 BMI reduction, or 2.0 cm waist reduction) within the observed dose range (Supplementary Figure S14)
Weight Management Dosages When used for weight management, semaglutide dosing follows a similar escalation schedule but may continue to increase beyond the typical diabetes maintenance dose
,
These cohorts were similar in terms of demographic and key clinical factors, despite disparities in the available sample sizes, providing confidence that the separation of these analyses did not impose selection bias on our study
M., Larsen, M., Sharma, S